Suppr超能文献

通过逆转录聚合酶链反应(RT-PCR)检测循环肿瘤细胞中癌胚抗原(CEA)信使核糖核酸(mRNA)的持续证据可预测早期复发:一项针对淋巴结阴性乳腺癌的前瞻性研究

Persistent evidence of circulating tumor cells detected by means of RT-PCR for CEA mRNA predicts early relapse: a prospective study in node-negative breast cancer.

作者信息

Jotsuka Toko, Okumura Yasuhiro, Nakano Shogo, Nitta Hidetoshi, Sato Takashi, Miyachi Masahiko, Suzumura Kazuyoshi, Yamashita Jun-ichi

机构信息

Department of Surgery, Aichi Medical University, Nagakute 21, Aichi 480-1195, Japan.

出版信息

Surgery. 2004 Apr;135(4):419-26. doi: 10.1016/j.surg.2003.08.014.

Abstract

BACKGROUND

In 100 consecutive patients with node-negative breast cancer who underwent curative surgery, we prospectively tested whether detection of circulating tumor cells in peripheral blood by means of reverse transcription-polymerase chain reaction for carcinoembryonic antigen (CEA) messenger RNA (mRNA) could predict patient outcomes.

METHODS

We performed reverse transcription-polymerase chain reaction in blood samples taken before surgery and in repeat samples taken 2 to 3 weeks after surgery. Univariate and multivariate analyses of relapse-free survival were performed.

RESULTS

Patients with CEA mRNA in preoperative samples had poorer survival rates than those who had no detectable CEA mRNA. The worst survival rate was seen in those with CEA mRNA in both pre- and postoperative samples. Stepwise multivariate analysis selected CEA mRNA expression pattern (P=.001; relative risk=0.69) and histologic tumor grade (P=.002; relative risk=1.35) as independent prognostic factors for disease-free survival.

CONCLUSIONS

Molecular detection of CEA mRNA in both pre- and postoperative blood samples is an independent, negative prognostic factor in patients with node-negative breast cancer undergoing curative surgery.

摘要

背景

在100例接受根治性手术的淋巴结阴性乳腺癌患者中,我们前瞻性地检测了通过逆转录聚合酶链反应检测外周血中癌胚抗原(CEA)信使核糖核酸(mRNA)来检测循环肿瘤细胞是否能够预测患者的预后。

方法

我们在手术前采集的血样以及术后2至3周采集的重复血样中进行逆转录聚合酶链反应。对无复发生存期进行单因素和多因素分析。

结果

术前样本中存在CEA mRNA的患者生存率低于未检测到CEA mRNA的患者。术前和术后样本中均存在CEA mRNA的患者生存率最差。逐步多因素分析选择CEA mRNA表达模式(P = 0.001;相对风险= 0.69)和组织学肿瘤分级(P = 0.002;相对风险= 1.35)作为无病生存的独立预后因素。

结论

术前和术后血样中CEA mRNA的分子检测是接受根治性手术的淋巴结阴性乳腺癌患者的独立不良预后因素。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验